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Take home message: We describe the design of InPedILD™, a study of 24 weeks’ 
nintedanib or placebo on top of standard of care, followed by variable duration open-label 
nintedanib in children with interstitial lung disease (ClinicalTrials.gov: NCT04093024) 
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Abstract  
Introduction: Childhood interstitial lung disease (chILD) comprises >200 rare respiratory 
disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces 
the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing ILDs. We 
present the design of a multicentre, prospective, double-blind, randomised, placebo-
controlled clinical trial of nintedanib in patients with fibrosing chILD (1199-0337 or 
InPedILD™; ClinicalTrials.gov: NCT04093024). 
Methods and analysis: Male or female children and adolescents aged 6–17 years (≥30; 
including ≥20 adolescents aged 12–17 years) with clinically significant fibrosing ILD will be 
randomised 2:1 to receive oral nintedanib or placebo on top of standard of care for 24 weeks 
(double-blind), followed by variable duration nintedanib (open-label). Nintedanib dosing will 
be based on body weight-dependent allometric scaling, with single-step dose reductions 
permitted to manage adverse events. Eligible patients will have evidence of fibrosis on high-
resolution computed tomography (within 12 months of their first screening visit), FVC ≥25% 
predicted, and clinically significant disease (Fan score of ≥3 or evidence of clinical 
progression over time). Patients with underlying chronic liver disease, significant pulmonary 
arterial hypertension, cardiovascular disease, or increased bleeding risk are ineligible. The 
primary endpoints are pharmacokinetics and the proportion of patients with treatment-
emergent adverse events at Week 24. Secondary endpoints include change in FVC% 
predicted from baseline, Pediatric Quality of Life Questionnaire™, oxygen saturation, and 6-
minute walk distance at Weeks 24 and 52. Additional efficacy and safety endpoints will be 
collected to explore long-term effects. #PedILD. #InPedILD. 
Keywords: interstitial lung disease in children; pulmonary fibrosis, nintedanib, childhood 
interstitial lung disease, chILD, parenchymal lung diseases (6/6) 
  
Introduction 
Childhood interstitial lung disease (chILD) comprises >200 rare heterogeneous respiratory 
disorders that can affect infants, children and adolescents [1, 2]. The prevalence (1.5–3.8 
cases per million [3-5]) and incidence (1.3 cases per million children [6]) of chILD may vary 
across different studies/analyses [1] depending on study design. chILD includes disorders 
that occur in adults as well as those unique to children, such as neuroendocrine cell 
hyperplasia of infancy and diseases attributed to genetic conditions and developmental 
processes [7]. Fibrosing forms of interstitial lung disease (ILD) involve an injurious process 
that can occur in both children and adults [1, 8]. It is not clear, however, whether the 
mechanism of fibrosis in the adult lung is similar to fibrosis in children who have ongoing 
alveolarisation [1]. 
Though fibrosing ILD in children has not been extensively studied and characterised, 
underlying conditions or contributing factors include surfactant dysfunction disorders such as 
mutations in SFTPC, ABCA3 and NKX2.1, connective tissue disease-related ILD, and 
radiation- or drug-induced fibrosis [1, 7, 9]. Similar to adults, subgroups of patients with 
fibrosing chILD exhibit a progressive phenotype characterised by worsening symptoms, lung 
function decline and increased morbidity [1, 10]. There are no approved therapies for ILD 
treatment in children and, based on anecdotal evidence, the current standard of care 
comprises the empiric use of systemic steroids, other (steroid-sparing) 
immunosuppressants, hydroxychloroquine or azithromycin [1, 11, 12].  
The tyrosine kinase inhibitor nintedanib potently blocks receptor and non-receptor tyrosine 
kinases that are implicated in the initiation and progression of pulmonary fibrosis, such as 
vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor 
receptors, fibroblast growth factor receptor kinase activity and Src family tyrosine kinases 
(e.g. Lck, Lyn and Flt-3) [13-15]. The antifibrotic effects of nintedanib have been 
demonstrated in various animal models of lung fibrosis resembling features of idiopathic 
pulmonary fibrosis (IPF) [16, 17], as well as in systemic sclerosis-associated ILD (SSc-ILD) 
[18] and rheumatoid arthritis-associated ILD [19]. Nintedanib treatment also decreased lung 
inflammation, granuloma formation and fibrosis in an animal model of silica-induced lung 
fibrosis [20] and reduced airway inflammation and remodelling following chronic allergic 
stimulation in ovalbumin-sensitised mice [21]. In animal models, nintedanib had an effect on 
tooth development and epiphyseal growth [22]. 
The benefits of nintedanib have been investigated in several fibrosing ILDs in adults, 
including IPF [23], SSc-ILD [24] and other progressive fibrosing ILDs (also described as 
chronic fibrosing ILDs with a progressive phenotype) [25]. Nintedanib is approved for the 
treatment of IPF, SSc-ILD and chronic fibrosing ILDs with a progressive phenotype in 
several countries [26, 27]. Across the clinical trial programme in adults, nintedanib is 
associated with a consistent and clinically meaningful slowing of the progressive decline in 
lung function as measured by forced vital capacity (FVC) over 52 weeks [23-25]. The most 
commonly reported adverse events (AEs) have been gastrointestinal disorders, including 
diarrhoea, which were mostly mild or of moderate intensity and amenable to treatment [23-
25]. Liver enzymes were also elevated in the nintedanib arms versus placebo [23-25].  
To date, there have been no clinical trials of antifibrotic agents in chILD. Based on its mode 
of action, preclinical effects in animal models of ILD, and clinical benefit in various 
progressive fibrosing ILDs in adults, the use of nintedanib treatment for children and 
adolescents with fibrosing ILD is compelling. Although it is not currently feasible to conduct a 
fully powered clinical trial of efficacy in this patient population, a clinical study evaluating the 
pharmacokinetics (PK) and safety of nintedanib in children and adolescents (6–17 years old) 
with clinically significant fibrosing ILD was designed. The primary objective of this 
randomised, placebo-controlled clinical trial (1199-0337 or InPedILD™; ClinicalTrials.gov: 
NCT04093024) is to inform the dosing and safety of nintedanib in this patient population. 
Efficacy assessment is also planned to explore the potential clinical benefit of nintedanib 
treatment in fibrosing chILD. 
Methods 
Trial design 
This study is a multicentre, multinational, prospective, randomised, placebo-controlled 
clinical trial of nintedanib on top of standard of care for 24 weeks (double-blind), followed by 
variable duration nintedanib (open-label) in children and adolescents with clinically 
significant fibrosing ILD. Patient recruitment is expected in ~24 countries and 70 sites (~1 
patient screened per site). 
Patients will undergo a 4-week screening period (Visit 1 to Visit 2). At Visit 2, patients 
meeting the eligibility criteria will be randomised to enter the study treatment period 
(comprising Part A and Part B) (Figure 1). During Part A, patients will be randomised (2:1) to 
receive blinded treatment (nintedanib or placebo) for 24 weeks. Patients will receive either 
oral nintedanib or placebo (twice daily [BID]) on top of standard of care, with starting doses 
(50mg, 75mg, 100mg or 150mg BID) based on patient weight using allometric scaling. 
Following completion of Part A (Visit 6), patients will receive open-label nintedanib (Part B) 
and will remain on treatment until the end of the study or discontinuation (variable from 
patient to patient).  
The study will end when ≥30 patients (including ≥20 adolescents aged 12–17 years) have 
completed PK sampling at 26 weeks or have prematurely discontinued the trial. Patients who 
complete the per protocol treatment period will be offered participation in a separate open-
label extension trial, if supported by the benefit–risk assessment performed at the end of the 
double-blind period. Following the treatment period or after early treatment discontinuation, 
patients will enter a 4-week follow-up period, unless they roll over into the open-label 
extension trial. 
Participants 
Eligible children and adolescents (aged 6–17 years) will have clinically significant fibrosing 
ILD with fibrosis on lung biopsy or high-resolution computed tomography (HRCT) based on 
central review by an independent reviewer. Due to the lack of published guidelines validating 
imaging features of fibrosis in children, imaging criteria established by expert consensus will 
be used to confirm eligibility and ensure consistency (Figure 2; Supplementary Methods).  
Table 1 details eligibility criteria. Patients with underlying chronic liver disease [28], clinically 
significant pulmonary arterial hypertension [29], cardiovascular disease [30] or increased risk 
of bleeding [31] are ineligible. Patients who have previously received nintedanib or another 
investigational therapy (within 1 month or 5 half-lives) are ineligible. Potential diagnoses 
likely associated with lung fibrosis include, but are not limited to: surfactant protein deficiency 
(SFTPC, ABCA3, NKX2.1 mutations); chronic hypersensitivity pneumonitis; toxic, radiation- 
and drug-induced pneumonitis; post-haematopoietic stem cell transplant fibrosis; and 
connective tissue disease-related disorders such as juvenile rheumatoid arthritis, juvenile 
idiopathic arthritis, SSc, dermatomyositis/polymyositis, mixed connective tissue disease or 
sarcoidosis. 
To match the systemic exposure reached in adult IPF, nintedanib doses (administered as 
soft capsules BID) will be based on body weight-dependent allometric scaling (scaling of 
adult clearance using an exponent of 0.75, consistent with the exponent estimated in 
population PK analyses in adults). A population mean nintedanib exposure of 80% to 125% 
compared with adult patients with IPF treated with 150mg BID was targeted for the 
determination of planned doses by body weight in the paediatric population (Supplementary 
Table 1). 
Dose reductions are permitted for drug-related AEs without prior interruption, i.e. 
immediately stepping down from one dose to the next dose. If the reduced dose is well 
tolerated, re-escalation is possible within 4 weeks following dose reduction in cases where 
AEs are considered drug related, or within 8 weeks in cases where AEs are not considered 
drug related. In cases of persistent AEs observed at the reduced dose, or severe effects at 
the starting dose, permanent treatment discontinuation should be considered. Temporary 
treatment interruption will be allowed to manage AEs. Dose reduction and re-increase are 
permitted on multiple occasions. 
Ethical approval and patient consent 
Trial initiation will occur at a site following review and approval by the respective institutional 
review board/independent ethics committee and competent authority according to national 
and international regulations. The trial will be conducted in accordance with the principles of 
the Declaration of Helsinki, International Conference on Harmonisation Guidelines, relevant 
sponsor standard operating procedures, and other relevant guidelines. Written informed 
consent and assent, where applicable, in accordance with the International Conference on 
Harmonisation Guidelines - Good Clinical Practice and local legislation, are required prior to 
trial participation.  
Randomisation and masking 
Eligible patients will be randomised to treatment groups according to a randomisation plan in 
a 2:1 ratio (nintedanib:placebo) at Visit 2 (i.e. the start of Part A) via Interactive Response 
Technology stratified by age group (6–<12 years; 12–<18 years). Access to the codes will be 
controlled and documented. Validated randomisation software will be used. 
Endpoints 
The primary endpoints are PK (area under the plasma concentration–time curve at steady 
state [AUCτ,ss] based on sampling at steady state [Weeks 2 and 26] just before drug 
administration, and 1, 2, 3, 4, 6 and 8 hours post dose) and the number (%) of patients with 
treatment-emergent AEs at Week 24 (Table 2).  
Secondary endpoints include change in FVC% predicted from baseline, Pediatric Quality of 
Life Questionnaire™ (PedsQL™), oxygen saturation (SpO2), and 6-minute walk distance at 
Week 24 and Week 52 (Table 2). Additional efficacy and safety endpoints will be collected to 
explore potential long-term effects (Table 2). 
Key assessments 
Figure 3 shows key assessments. A complete physical examination and electrocardiogram 
will be performed at specific time points throughout the study. Potential bone toxicity will be 
monitored using serial assessment of leg length, height and imaging of growth plates in 
those patients with open physes. A routine dental examination with imaging will be carried 
out to monitor potential dental toxicity. 
AEs will be coded using the Medical Dictionary for Drug Regulatory Activities, and all AEs 
with an onset between start of treatment and 28 days after the last dose of trial medication 
will be assigned to the on-treatment period for evaluation. For the primary safety analysis, 
treatment-emergent AEs during the double-blind period until Week 24 (Part A) will be 
included. A separate analysis over the whole trial period including all treatment-emergent 
AEs will be performed. All treated patients will be included in the safety analysis. 
While the study is not powered to detect treatment differences in efficacy outcomes like 
changes in FVC% predicted from baseline, efficacy assessments are planned to elucidate 
disease course and potential trends for treatment effect. FVC will be assessed using 
standardised spirometry equipment (ERT SpiroSphere®) [32], with predicted values 
calculated according to the Global Lung Initiative [33]. SpO2 will be measured with room air 
at rest by standard pulse oximetry (earlobe or forehead). Exercise capacity will be assessed 
using the 6-minute walk test. Health-related quality of life will be assessed using PedsQL™ 
[34]. Time to first acute exacerbation (details provided in the Supplementary Methods), 
respiratory-related hospitalisation and time to death (all-cause mortality) will be documented.  
Additional assessments 
Serum biomarker samples will be collected and submitted to the central laboratory (Visits 2, 
5, 6, 8 and 9 only). In selected sites, patients will have the option to participate in a 
longitudinal HRCT sub-study. HRCT scans will be performed at baseline, 52 weeks and 100 
weeks, to identify potential predictors of progression, evaluate the association between 
HRCT-derived imaging and clinical parameters, and investigate computer-aided analysis for 
the characterisation and monitoring of chILD. 
Statistical analysis 
Target sample size is based on the sample size estimation for the evaluation of the primary 
endpoint of PK and trial feasibility evaluation. For the primary evaluation of PK, the 
clearance parameter needs to be estimated with adequate precision. Assuming variability of 
the clearance parameter is comparable between children and adults, at least 20 patients 
with available PK measurements per age group (6–<12 years; 12–<18 years) are needed to 
achieve at least 80% probability (loosely referred to as power in this context [35]) of having 
the 95% confidence interval of nintedanib CL/Fss and with this AUCτ,ss within 60% and 140% 
of the geometric mean estimate, calculated as described by Wang et al. [35]. PK 
assessment will be performed using non-compartmental analyses and population PK 
analyses exploring relevant covariates on PK (age and body weight). 
An external safety monitoring committee will advise the study team and may recommend 
intermediate checks in those patients who switch from placebo to nintedanib at the end of 
the initial 24 weeks of treatment. An independent disease review committee will evaluate 
inclusion criteria of all screened participants, retrospectively, while an independent 
adjudication committee will review all fatal cases and adjudicate all deaths to either cardiac, 
respiratory or other causes, and review all AEs categorised as major adverse cardiovascular 
events.  
Safety analyses will be descriptive. As this is an exploratory study, with no confirmatory 
testing, analysis of secondary endpoints will be descriptive and no adjustment for multiple 
testing will be performed. Continuous endpoints will be analysed using a mixed model with 
repeated measurements. Time-to-event endpoints will be displayed descriptively using the 
Kaplan–Meier method. Categorical endpoints, safety and tolerability will be displayed 
descriptively in frequency tables. 
Discussion 
This is the first randomised controlled trial of an antifibrotic agent in chILD, a group of 
disorders that are currently managed with limited, mainly supportive treatments [1]. Results 
will inform both the dose-exposure and safety profile of nintedanib in children aged ≥6 years.  
Development of this study protocol required international collaboration to create a clinical 
trial framework in a disease area with no previous clinical trials. Unique challenges with the 
trial design include uncertainty regarding: 1) the prevalence of fibrotic ILD in children; 2) 
numbers of patients who will meet specific eligibility criteria; 3) the natural history of fibrosing 
ILD in children; 4) variable chILD clinical practice patterns worldwide; 5) limitations in 
validation of outcome measures; 6) considerations of safety and efficacy assessments when 
performing a study in children with ongoing lung and somatic growth. These factors 
impacted the approach to the study protocol as intense resource allocation was required to 
prepare for the implementation and standardisation of sites across a large number of 
countries due to the low prevalence of fibrotic ILD in children.  
Similar to trials in adult fibrosing ILD [36, 37], a basket approach is being used to group 
children and adolescents according to demonstrated evidence of lung fibrosis and clinical 
disease severity, irrespective of the underlying clinical diagnosis. Hence, a major limitation of 
this study is the heterogeneous study population, especially in evaluating efficacy outcomes 
including lung function. An extensive characterisation of the patient population is needed 
given the differences in physiology, risk and outcome of ILD between adults and children. 
Nintedanib inhibits several growth factors that are implicated in the development of IPF and 
other fibrosing ILDs [13-15] but may be important for lung development, e.g. VEGF [38]. 
Although most alveolarisation occurs by age 2 years [39], lung function increases throughout 
childhood and adolescence, and it is unclear how nintedanib may affect this process. Based 
on limited evidence to support the potential benefit versus risk of nintedanib in the growing 
lung and possible additional risks, including tooth development and the difficulty with 
assessing eligibility criteria, patients aged <6 years will be excluded from this study.  
The minimum target of 30 patients and treatment duration of 24 weeks allow for adequate 
assessment of both systemic exposure and the tolerability profile of nintedanib in the target 
population. The planned dosing regimen aims to achieve nintedanib exposures in paediatric 
patients “similar” to those in adults (exposure-matching). The same dose/exposure across 
different ILDs was effective, supporting the use of the same exposure in chILD. This 
approach was chosen based on preclinical evidence that demonstrated antifibrotic activity of 
nintedanib at similar doses in several animal models of lung fibrosis [15]. Prediction of AEs 
and estimation of treatment effects are complicated by limited data on the natural history of 
chILD. A placebo group may allow exploratory evaluation of the natural course of lung 
function and assessment of the background of AEs in this patient population. 
Nonetheless, evaluating potential clinical benefit in this paediatric subset is challenging. As 
children grow, increases in lung volume result in increased FVC, and there is the potential 
that FVC will increase in children with fibrosing ILD treated with nintedanib. This is in 
comparison with trials of fibrosing ILD in adults, where efficacy was demonstrated based on 
a decrease in FVC decline [25]. The benefits of improving lung structure and helping to 
achieve maximum lung function prior to reaching 18–21 years of age (before lung function 
decline begins) may have critical effects on morbidity and mortality. To support the 
extrapolation of the nintedanib treatment effect from adults to children, an assessment of 
whether data from clinical trials with nintedanib in adults can be used for the evaluation of 
the treatment effect in this paediatric trial (e.g. by incorporating the treatment effect of 
nintedanib in adult patients with ILDs as prior information using a Bayesian approach) is 
planned. 
While the safety profile in chILD is presumed to be similar to that observed in the adult 
studies of IPF, SSc-ILD and progressive fibrosing ILDs [23-25], there are no data on 
nintedanib use in children. To maintain patient safety, AE monitoring includes guidelines for 
management of diarrhoea and liver function test abnormalities, imaging and clinic exams to 
monitor potential bone and dental toxicity, as well as an unblinded safety monitoring 
committee. Preclinical data [22] and clinical data from other VEGF inhibitors suggest that 
any potential effects on bones will be reversible with drug discontinuation. The dental toxicity 
noted in previous rodent studies of nintedanib has not been replicated in primate models 
[22], nor seen with other VEGF inhibitors in children. However, dental monitoring will be 
implemented to allow for early detection of any potential effects. The placebo arm will assist 
in the interpretation of any unexpected findings (positive or negative) in this paediatric 
population. 
Given the high unmet medical need, lack of therapeutic options and the potential for a robust 
assessment of efficacy, this study design has required new thinking around the definitions 
and outcome measures of pulmonary fibrosis in children. In addition to providing data about 
the use and safety of nintedanib in children and adolescents with fibrosing ILD, the results of 
this trial will contribute to our understanding of the natural history and characterisation of 
lung impairment. The experience gained from this study will inform future interventional 
studies of rare paediatric diseases.  
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Table 1: Full inclusion and exclusion criteria 
Inclusion criteria 
Male or female children and adolescents aged 6–17 years old at Visit 2 
Written informed consent and assent (where applicable) prior to admission to the trial 
Female subjects of childbearing potential must confirm that sexual abstinence is standard 
practice and will be continued until 3 months after last drug intake, or agree to use a 
highly effective method of birth control from 28 days prior to initiation of study treatment, 
during treatment and until 3 months after last drug intake 
Evidence of fibrosing ILD* on HRCT within 12 months of Visit 1 as assessed by the 
investigator and confirmed by central review 
FVC% predicted ≥25% at Visit 2† 
Clinically significant disease at Visit 2, as assessed by the investigator based on any of 
the following: 
 Fan score ≥3 [10], or 
 Documented evidence of clinical progression over time based on either: 
o 5–10% relative decline in FVC% predicted accompanied by worsening 
symptoms, or 
o a ≥10% relative decline in FVC% predicted, or 
o increased fibrosis on HRCT, or 
o other measures of clinical worsening attributed to progressive lung 
disease (e.g. increased oxygen requirement, decreased diffusion capacity) 
Exclusion criteria 
AST and/or ALT >1.5 x ULN at Visit 1‡ 
Bilirubin >1.5 x ULN at Visit 1‡ 
Creatinine clearance <30 mL/min calculated by Schwartz formula at Visit 1‡ 
Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment) 
at Visit 1 
Previous treatment with nintedanib 
Other investigational therapy received within 1 month or 5 half-lives (whichever is shorter 
but ≥1 week) prior to Visit 2 
Significant PAH defined by any of the following: 
 Previous clinical or echocardiographic evidence of significant right heart failure 
 History of right heart catheterisation showing a cardiac index ≤2 l/min/m² 
 PAH requiring parenteral therapy with epoprostenol/treprostinil 
Other clinically significant pulmonary abnormalities (investigator-assessed) 
Cardiovascular diseases (any of the following): 
 Severe hypertension (uncontrolled with treatment), within 6 months of Visit 1. 
Uncontrolled hypertension is defined as: 
o Children aged 6–≤12 years: ≥95th percentile + 12 mm Hg or ≥140/90 mm 
Hg (whichever is lower) (systolic or diastolic blood pressure equal to or 
greater than the calculated target value) 
o In adolescents aged 13–17 years: systolic blood pressure ≥140 mm Hg or 
diastolic blood pressure ≥90 mm Hg 
 Myocardial infarction within 6 months of Visit 1 
 Unstable cardiac angina within 6 months of Visit 1 
Bleeding risk, defined as any of the following: 
 Known genetic predisposition to bleeding 
 Patients who require: 
o Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K 
antagonists, direct thrombin inhibitors, heparin, hirudin) 
o High-dose antiplatelet therapy§ 
 History of haemorrhagic CNS event within 12 months of Visit 1 
 Any of the following within 3 months of Visit 1: 
o Haemoptysis or haematuria 
o Active GI bleeding or GI ulcers 
o Major injury or surgery (investigator-assessed) 
 Any of the following coagulation parameters at Visit 1: 
o INR >2 
o Prolongation of PT by >1.5 x ULN 
o Prolongation of aPTT by >1.5 x ULN 
History of thrombotic event (including stroke and transient ischaemic attack) within 12 
months of Visit 1 
Known hypersensitivity to the trial medication or its components (i.e. soya lecithin) 
Documented allergy to peanut or soya 
Other disease that may interfere with testing procedures or in the judgement of the 
investigator may interfere with trial participation or may put the patient at risk when 
participating in this trial 
Life expectancy for any concomitant disease other than ILD <2.5 years (investigator-
assessed) 
Female patients who are pregnant, nursing, or who plan to become pregnant while in the 
trial 
Patients not able or willing to adhere to trial procedures, including intake of study 
medication 
Patients with any diagnosed growth disorder such as growth hormone deficiency or any 
genetic disorder that is associated with short stature (e.g. Turner syndrome, Noonan 
syndrome, Russell–Silver syndrome) and/or treatment with growth hormone therapy 
within 6 months before Visit 2¶ 
Patients <13.5 kg of weight at Visit 1 (same threshold for male and female patients) 
* Clinically significant fibrosing ILD will be confirmed based on documented evidence of 
fibrosing features on HRCT or lung biopsy, as defined in the Participants section of the 
Methods. 
† Predicted normal values will be calculated according to the Global Lung Initiative. 
‡ Laboratory parameters from Visit 2 will only be available after randomisation and, if the 
result no longer satisfies the entry criteria, the investigator will decide whether the patient 
should remain on study drug. Abnormal laboratory parameters at Visit 1 are allowed to be re-
tested (once) if it is thought that there was a measurement error or if they are a result of a 
temporary and reversible medical condition (once that condition has resolved). 
§ Prophylactic low-dose heparin or heparin flush as needed for maintenance of an indwelling 
intravenous device, as well as prophylactic use of antiplatelet therapy, are not prohibited. 
¶ Patients with short stature considered by the investigator to be due to glucocorticoid 
therapy may be included. 
ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate 
aminotransferase; CNS, central nervous system; GI, gastrointestinal; FVC, forced vital 
capacity; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; 
INR, international normalised ratio; PAH, pulmonary arterial hypertension; PT, prothrombin 
time; ULN, upper limit of normal. 
  
Table 2: Study endpoints 
Primary endpoints: 
Pharmacokinetics: AUCτ,ss based on sampling at steady state (at Week 2 and Week 
26) 
Number (%) of patients with treatment-emergent AEs at Week 24 
Secondary endpoints: 
Number (%) of patients with treatment-emergent pathological findings of epiphyseal 
growth plate on imaging at Week 24 and Week 52* 
Number (%) of patients with treatment-emergent pathological findings on dental 
examination or imaging at Week 24 and Week 52* 
Number (%) of patients with treatment-emergent AEs over the whole trial 
Change in height, sitting height, leg length from baseline at Week 24, Week 52*, Week 
76* and Week 100* 
Change in FVC% predicted from baseline at Week 24 and Week 52* 
Absolute change from baseline in PedsQL™ at Week 24 and Week 52* 
Change in SpO2 on room air at rest from baseline at Week 24 and Week 52* 
Change in 6-min walk distance from baseline at Week 24 and Week 52* 
Patient acceptability based on the size of capsules at Week 24 
Patient acceptability based on the number of capsules at Week 24 
Time to first respiratory-related hospitalisation over the whole trial 
Time to first acute ILD exacerbation or death over the whole trial 
Time to death over the whole trial 
Further endpoints 
Number (%) of patients with increase/decrease in FVC% predicted (5–10%; >10%) at 
Week 24 and Week 52* 
Number (%) of patients with ≥4.4-point increase in PedsQL™ from baseline at Week 
24 and Week 52* 
Number (%) of patients with >4% increase in SpO2 on room air from baseline at Week 
24 and Week 52* 
Change in calculated Fan severity score from baseline at Week 24 and Week 52* 
Change in HAZ score from baseline at Week 24 and Week 52* 
Change in WAZ score from baseline at Week 24 and Week 52* 
Slope of HAZ over whole trial 
Slope of WAZ over whole trial 
Number of missed school days due to the disease under study at Week 24 
Absolute change from baseline in log-transformed CA-125 at Week 24 and Week 52 







* 52 weeks, 76 weeks, and 100 weeks time points will not be available for all patients. 
Other parameters may be calculated as deemed appropriate. 
AE, adverse event; AUCτ,ss, area under the plasma concentration–time curve at steady state; 
CL/Fss, apparent clearance of the analyte in the plasma at steady state following 
extravascular multiple dose administration; Cmax,ss, maximum measured concentration of the 
analyte in plasma at steady state; Cpre,ss, pre-dose concentration of the analyte in plasma at 
steady state immediately before administration of the next dose; FVC, forced vital capacity; 
HAZ; height-for-age z-score; ILD, interstitial lung disease; PedsQL™, Pediatric Quality of 
Life Questionnaire™; SpO2, oxygen saturation; t1/2,ss, terminal half-life of the analyte in 
plasma at steady state; tmax,ss, time from dosing to maximum measured concentration of the 
analyte in plasma at steady state; Vz/Fss, apparent volume of distribution during the terminal 




Figure 1: Study design 
EoT, end of treatment; FPE, first patient enrolled; FPI, first patient in; LPI, last patient in. 
Figure 2: Inclusion criteria for fibrosing ILD 
Evidence of fibrosing ILD will be confirmed by central review (lung biopsy and HRCT). 
* Coexisting cystic abnormalities or ground-glass opacity are acceptable; however, 
coexisting multifocal non-fibrotic, non-dependent consolidations (e.g. organising pneumonia, 
infection) will not be permitted. 
† With or without ground-glass opacification. 
HRCT, high-resolution computed tomography; ILD, interstitial lung disease; NSIP, non-
specific interstitial pneumonia; UIP, usual interstitial pneumonia. 
Figure 3: Key assessments 
* Part A comprises Visit 2 (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 5 (Week 12), 
and Visit 6 (Week 24). Laboratory tests can be performed between Visit 5 and 6 (Visit 5A) as 
needed. 
† Part B starts at the end of Visit 6 and comprises Visit 7 (Week 26), Visit 8 (Week 36), Visit 
9 (Week 52), Visit X (Week 64, then every 12 weeks until EoT), and EoT. Laboratory tests 
can be performed between each visit (Visit 7A, 8A, 9A and XA as needed). 
‡ The primary endpoints are PK (AUCτ,ss) based on sampling at steady state (Weeks 2 and 
26) and number (%) of patients with treatment-emergent adverse events (Week 24). 
§ Clinically significant disease is assessed by the investigator based on any of the following: 
Fan score ≥3 or documented evidence of clinical progression over time (either 5–10% 
relative decline in FVC% predicted accompanied by worsening symptoms, or a ≥10% 
relative decline in FVC% predicted, or increased fibrosis on HRCT, or other measures of 
clinical worsening attributed to progressive lung disease [e.g. increased oxygen requirement, 
decreased diffusion capacity]). 
6MWT, 6-minute walk test; AUCτ,ss, area under the plasma concentration–time curve at 
steady state; DLCO, diffusing capacity of the lung for carbon monoxide; ECG, 
electrocardiogram; EoT, end of treatment; FVC, forced vital capacity; HRCT, high-resolution 
computed tomography; ILD, interstitial lung disease; PedsQL™, Pediatric Quality of Life 
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Inclusion criteria for fibrosing ILD 
For patients with previous pathological findings of fibrosis on lung biopsy, confirmation of 
fibrosis on high-resolution computed tomography (HRCT) will be made if at least one of the 
following imaging criteria are met within 12 months of screening (Visit 1), as confirmed by 
central review: reticular abnormality or traction bronchiectasis or architectural distortion (with 
or without ground-glass opacification) or honeycombing. Coexisting cystic abnormalities or 
ground-glass opacities are acceptable; however, coexisting multifocal non-fibrotic, non-
dependent consolidations (e.g. organising pneumonia, infection) will not be permitted.  
Any of the following lung biopsy findings or diagnoses will be accepted as documentation of 
fibrosis, as confirmed by central review: non-specific interstitial pneumonia (fibrosing); usual 
interstitial pneumonia; evidence of interstitial fibrosis on a significant component of the lung 
biopsy (based on the opinion of the central reviewer); evidence of lobular remodelling on a 
significant component of the lung biopsy (based on the opinion of the central reviewer); or 
honeycomb lung. For patients without any documented lung biopsy or whose biopsy results 
do not meet the biopsy criteria for fibrosis listed above, at least two of the aforementioned 
imaging findings are required on at least two HRCT scans. 
Definition of acute exacerbation in chILD 
Acute exacerbation will be defined as a significant worsening of the patient’s respiratory 
condition that necessitates a change in regular management, based on >2 of the following 
criteria over 4 weeks: increase in respiratory rate ≥20% from baseline; increase in or 
development of dyspnoea; newly developing or increased abnormalities on chest imaging; 
onset/increase of oxygen demand to attain the individual baseline saturation (at rest and/or 
during exercise); need for an additional level of ventilatory support (in addition to oxygen); 
decrease in vital capacity ≥10% from baseline in children able to perform the test; or reduced 






















1 13.5* to 
<23.0 
50 mg 25 mg (2) 25 mg 25 mg (1) 
2 23.0 to 
<33.5 
75 mg 25 mg (3) 50 mg 25 mg (2) 
3 33.5 to 
<57.5 
100 mg 100 mg (1) or 
25 mg (4) 
75 mg 25 mg (3) 
4 ≥57.5 150 mg 150 mg (1) or 
25 mg (6) 
100 mg 100 mg (1) or 
25 mg (4) 
* Patients <13.5 kg of weight will be excluded from the trial. 
BID, twice daily. 
